Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

Y. Yamada, M. Tahara, T. Miya, T. Satoh, K. Shirao, Y. Shimada, A. Ohtsu, Y. Sasaki, Yusuke Tanigawara

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35-40% with good tolerability in patients with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional 5-fluorouracil/leucovorin plus oxaliplatin, the recommended dose (RD) of SOX was determined, and its safety and preliminary efficacy were evaluated in a phase I/II study. Oxaliplatin was administered at a dose of 100 mg m-2 (level 1) or 130 mg m-2 (level 2) on day 1, and S-1 (80-120) was given twice daily for 2 weeks followed by a 1-week rest. This schedule was repeated every 3 weeks. Level 2 was determined to be the RD. For the 28 patients who received the RD, the median treatment course was 6.5 cycles (2-14), RR of 50% (1 CR and 13 PR: 95% CI 31-69%), with a median progression-free survival of 196 days. Survival rate (1 year) was 79%. Peripheral neuropathy was observed in all patients but with no functional disorders. Major grade 3 or 4 adverse reactions at the RD were neutropaenia (14%), thrombocytopaenia (28%), and diarrhoea (3%). SOX regimen is effective and easily manageable without central vein access.

Original languageEnglish
Pages (from-to)1034-1038
Number of pages5
JournalBritish Journal of Cancer
Volume98
Issue number6
DOIs
Publication statusPublished - 2008 Mar 25

Fingerprint

oxaliplatin
Colorectal Neoplasms
Therapeutics
Leucovorin
Peripheral Nervous System Diseases
Fluorouracil
Disease-Free Survival
Veins
Diarrhea
Appointments and Schedules
Survival Rate
Safety

Keywords

  • Colorectal cancer
  • Oxaliplatin
  • Phase I/II
  • S-1
  • SOX

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. / Yamada, Y.; Tahara, M.; Miya, T.; Satoh, T.; Shirao, K.; Shimada, Y.; Ohtsu, A.; Sasaki, Y.; Tanigawara, Yusuke.

In: British Journal of Cancer, Vol. 98, No. 6, 25.03.2008, p. 1034-1038.

Research output: Contribution to journalArticle

Yamada, Y. ; Tahara, M. ; Miya, T. ; Satoh, T. ; Shirao, K. ; Shimada, Y. ; Ohtsu, A. ; Sasaki, Y. ; Tanigawara, Yusuke. / Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. In: British Journal of Cancer. 2008 ; Vol. 98, No. 6. pp. 1034-1038.
@article{fc1453956df14193a0377b9cea46aa04,
title = "Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer",
abstract = "Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35-40{\%} with good tolerability in patients with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional 5-fluorouracil/leucovorin plus oxaliplatin, the recommended dose (RD) of SOX was determined, and its safety and preliminary efficacy were evaluated in a phase I/II study. Oxaliplatin was administered at a dose of 100 mg m-2 (level 1) or 130 mg m-2 (level 2) on day 1, and S-1 (80-120) was given twice daily for 2 weeks followed by a 1-week rest. This schedule was repeated every 3 weeks. Level 2 was determined to be the RD. For the 28 patients who received the RD, the median treatment course was 6.5 cycles (2-14), RR of 50{\%} (1 CR and 13 PR: 95{\%} CI 31-69{\%}), with a median progression-free survival of 196 days. Survival rate (1 year) was 79{\%}. Peripheral neuropathy was observed in all patients but with no functional disorders. Major grade 3 or 4 adverse reactions at the RD were neutropaenia (14{\%}), thrombocytopaenia (28{\%}), and diarrhoea (3{\%}). SOX regimen is effective and easily manageable without central vein access.",
keywords = "Colorectal cancer, Oxaliplatin, Phase I/II, S-1, SOX",
author = "Y. Yamada and M. Tahara and T. Miya and T. Satoh and K. Shirao and Y. Shimada and A. Ohtsu and Y. Sasaki and Yusuke Tanigawara",
year = "2008",
month = "3",
day = "25",
doi = "10.1038/sj.bjc.6604271",
language = "English",
volume = "98",
pages = "1034--1038",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

AU - Yamada, Y.

AU - Tahara, M.

AU - Miya, T.

AU - Satoh, T.

AU - Shirao, K.

AU - Shimada, Y.

AU - Ohtsu, A.

AU - Sasaki, Y.

AU - Tanigawara, Yusuke

PY - 2008/3/25

Y1 - 2008/3/25

N2 - Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35-40% with good tolerability in patients with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional 5-fluorouracil/leucovorin plus oxaliplatin, the recommended dose (RD) of SOX was determined, and its safety and preliminary efficacy were evaluated in a phase I/II study. Oxaliplatin was administered at a dose of 100 mg m-2 (level 1) or 130 mg m-2 (level 2) on day 1, and S-1 (80-120) was given twice daily for 2 weeks followed by a 1-week rest. This schedule was repeated every 3 weeks. Level 2 was determined to be the RD. For the 28 patients who received the RD, the median treatment course was 6.5 cycles (2-14), RR of 50% (1 CR and 13 PR: 95% CI 31-69%), with a median progression-free survival of 196 days. Survival rate (1 year) was 79%. Peripheral neuropathy was observed in all patients but with no functional disorders. Major grade 3 or 4 adverse reactions at the RD were neutropaenia (14%), thrombocytopaenia (28%), and diarrhoea (3%). SOX regimen is effective and easily manageable without central vein access.

AB - Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35-40% with good tolerability in patients with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional 5-fluorouracil/leucovorin plus oxaliplatin, the recommended dose (RD) of SOX was determined, and its safety and preliminary efficacy were evaluated in a phase I/II study. Oxaliplatin was administered at a dose of 100 mg m-2 (level 1) or 130 mg m-2 (level 2) on day 1, and S-1 (80-120) was given twice daily for 2 weeks followed by a 1-week rest. This schedule was repeated every 3 weeks. Level 2 was determined to be the RD. For the 28 patients who received the RD, the median treatment course was 6.5 cycles (2-14), RR of 50% (1 CR and 13 PR: 95% CI 31-69%), with a median progression-free survival of 196 days. Survival rate (1 year) was 79%. Peripheral neuropathy was observed in all patients but with no functional disorders. Major grade 3 or 4 adverse reactions at the RD were neutropaenia (14%), thrombocytopaenia (28%), and diarrhoea (3%). SOX regimen is effective and easily manageable without central vein access.

KW - Colorectal cancer

KW - Oxaliplatin

KW - Phase I/II

KW - S-1

KW - SOX

UR - http://www.scopus.com/inward/record.url?scp=40849136304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849136304&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604271

DO - 10.1038/sj.bjc.6604271

M3 - Article

VL - 98

SP - 1034

EP - 1038

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -